A health services research agenda for cellular, molecular and genomic technologies in cancer care

Public Health Genomics

Volumn 12, Issue 4, 2009, Pages 233-244

  Wideroff, Louise ^a,q   Phillips, Kathryn A ^b   Randhawa, Gurvaneet ^c   Ambs, Anita ^a   Armstrong, Katrina ^d   Bennett, Charles L ^e   Brown, Martin L ^a   Donaldson, Molla S ^f   Follen, Michele ^g   Goldie, Sue J ^h   Hiatt, Robert A ^b   Khoury, Muin J ^j   Lewis, Graham ^p   McLeod, Howard L ^k   Piper, Margaret ^l   Powell, Isaac ^m   Schrag, Deborah ⁱ   Schulman, Kevin A ⁿ   Scott, Joan ^o  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l Blue Cross and Blue Shield Association   (United States)

^m WAYNE STATE UNIVERSITY   (United States)

ⁿ DUKE UNIVERSITY   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

^p UNIVERSITY OF YORK   (United Kingdom)

^q NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

more..

Author keywords

Emerging technologies; Genomics; Health services research; Translational research

Indexed keywords

CANCER PATIENT; CLINICAL EFFECTIVENESS; ECONOMIC ASPECT; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICES RESEARCH; HIGH RISK POPULATION; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT; GENETICS; GENOMICS; HEALTH CARE DELIVERY; HUMAN; NEOPLASM; ORGANIZATION AND MANAGEMENT; SOCIAL JUSTICE;

CONTINUITY OF PATIENT CARE; GENOMICS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES RESEARCH; HUMANS; NEOPLASMS; QUALITY OF HEALTH CARE; SOCIAL JUSTICE;

EID: 67449086758     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203779     Document Type: Review

References (83)

1. Moses H, Dorsey ER, Matheson DH, Thier SO: Financial anatomy of biomedical research. JAMA 2005; 294: 1333-1342.
2. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006; 12: 3661-3697.
3. Deverka PA, Doksum T, Carlson RJ: Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin Pharmacol Ther 2007; 82: 427-434.
4. American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21: 2397-2406.
5. Mueller NE, Birmann BM, Parsonnet J, Schiffman MH, Stuver SO: Infectious agents; in Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention. New York, Oxford University Press, 2006, pp 507-548.
6. Gish RG, Locarnini SA: Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4: 666-676.
7. Wheeler CM: Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 2007; 4: 224-235.
8. Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, et al: Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006; 102: 552-562.
9. Kundi M: New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133-140.
10. Wagner PD, Verma M, Srivastava S: Challenges for biomarkers in cancer detection. Ann NY Acad Sci 2004; 1022: 9-16.
11. O'Connell CD, Atha DH, Jakupciak JP: Standards for validation of cancer biomarkers. Cancer Biomark 2005; 1: 233-239.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
13. Sherbenou DW, Druker BJ: Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117: 2067-2074.
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
15. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 2006; 98: 1183-1192.
16. Miller CR, McLeod HL: Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 2007; 5: 9-14.
17. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4: e209.
18. Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-1659.
19. Vicent MJ, Duncan R: Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006; 24: 39-47.
20. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.
21. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
22. Rodgers GM: Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia. Oncology 2006; 20(suppl 6):12-15.
23. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, et al: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439-449.
24. Torigian DA, Huang SS, Houseni M, Alavi A: Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 2007; 57: 206-224.
25. Sokolov K, Aaron J, Hsu B, Nida D, Gillenwater A, Follen M, et al: Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat 2003; 2: 491-504.
26. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR: American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22: 3631-3638.
27. Jacobellis J, Martin L, Engel J, VanEenwyk J, Bradley LA, Kassim S, et al: Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing - Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morb Mortal Wkly Rep 2004; 53: 603-606.
28. Vadaparampil ST, Wideroff L, Olson L, Viswanath V, Freedman AN: Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 2005; 135: 41-46.
29. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al: The research on adverse drug events and reports (RADAR) project. JAMA 2005; 293: 2131-2140.
30. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA: Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005; 165: 2331-2336.
31. Winn-Deen ES: Standards and controls for genetic testing. Cancer Biomark 2005; 1: 217-220.
32. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al: Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002; 156: 311-318.
33. Schoenhagen P: The role of coronary CT angiography (CTA) for patients presenting with acute chest pain: defining problem-specific, evidence-based indications of a novel imaging modality. Int J Cardiovasc Imaging 2007; 23: 429-432.
34. Vaucher YE, Pretorius DH: Brain imaging in neonatal clinical trials: in search of a gold standard. J Pediatr 2007; 150: 575-577.
35. Phillips KA, Van Bebber SL, Issa AM: Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Personalized Med 2006; 3: 411-414.
36. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J: Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004; 10: 425-432.
37. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, et al: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant therapy. J Natl Cancer Inst 2007; 99: 196-205.
38. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, et al: Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
39. Lipscomb J, Donaldson MS, Hiatt RA, et al: Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr 2004; 33: 1-7.
40. Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004; 5: 663-669.
41. Constable S, Johnson MR, Pirmohamed M: Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn 2006; 6: 193-205.
42. Dervieux T, Bala MV: Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006; 7: 1175-1184.
43. Hiatt RA, Rimer BK: A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 1999; 8: 957-964.
44. Guttmacher AE, Porteous ME, McInerney JD: Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007; 8: 151-157.
45. McInerney J:Education in a genomics world. J Med Philos 2002; 27: 369-390.
46. Penchansky R, Thomas JW: The concept of access: definition and relationship to consumer satisfaction. Med Care 1981; 19: 127-140.
47. McLaughlin CG, Wyszewianski L: Access to care: remembering old lessons. Health Serv Res 2002; 37: 1441-1443.
48. Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol 2007; 25: 180-186.
49. Kim P: Cost of cancer care: the patient perspective. J Clin Oncol 2007; 25: 228-232.
50. Kabe KL, Kolesar JM: Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm 2006; 63: 527-533.
51. Eng C, Iglehart D: Decision aids from genetics to treatment of breast cancer: long-term clinical utility or temporary solution? JAMA 2004; 292: 496-498.
52. Salsberg E, Erikson C: The changing physician workforce landscape: implications for physical medicine and rehabilitation. Am J Phys Med Rehabil 2007; 86: 838-844.
53. Armstrong K, Micco E, Carney A, Stopfer J, Putt M: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 2005; 293: 1729-1736.
54. Krieger N: Defining and investigating social disparities in cancer: critical issues. Cancer Causes Control 2005; 16: 5-14.
55. Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ: Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health 2006; 96: 2113-2121.
56. Hall MJ, Olopade OI: Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006; 24: 2197-2203.
57. Phillips KA, Veenstra D, Van Bebber S, Sakowski J: An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003; 4: 231-239.
58. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004; 22: 854-863.
59. Goldie SJ, Levin AR: Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA 2001; 286: 1637-1638.
60. Goldie S: A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynaecol Obstet 2006; 94(suppl 1):S95-S105.
61. Wingo PA, Howe HL, Thun MJ, Ballard-Barbash R, Ward E, Brown ML, et al: A national framework for cancer surveillance in the United States. Cancer Causes Control 2005; 16: 151-170.
62. Hiatt RA: The future of cancer surveillance. Cancer Causes Control 2006; 17: 639-646.
63. Haux R: Health information systems - past, present, future. Int J Med Inform 2006; 75: 268-281.
64. Lobach DF, Detmer DE: Research challenges for electronic health records. Am J Prev Med 2007; 32:S104-S111.
65. Deapen D: Cancer surveillance and information: balancing public health with privacy and confidentiality concerns (United States). Cancer Causes Control 2006; 17: 633-637.
66. McDonald IG: Quality assurance and technology assessment: pieces of a larger puzzle. J Qual Clin Pract 2000; 20: 87-94.
67. Sussman S, Valente TW, Rohrbach LA, Skara S, Pentz MA: Translation in the health professions: converting science into action. Eval Health Prof 2006; 29: 7-32.
68. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-674.
69. Col NF: The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant? Med Decision Making 2003; 23: 441-448.
70. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP: Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006; 24(suppl 3): S155-S163.
71. O'Sullivan AK, Thompson D, Drummond MF: Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health 2005; 8: 67-79.
72. Rogowski W: Current impact of gene technology on health care: a map of economic assessments. Health Policy 2007; 80: 340-357.
73. Torti FM Jr, Reed SD, Schulman KA: Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. Value Health 2006; 9: 281-291.
74. Sellers TA, Caporaso N, Lapidus S, Petersen GM, Trent J: Opportunities and barriers in the age of team science: strategies for success. Cancer Causes Control 2006; 17: 229-237.
75. McGuire DB: Building and maintaining an interdisciplinary research team. Alzheimer Dis Assoc Disord 1999; 13(suppl 1):S17-S21.
76. Halbert CH, Armstrong K, Gandy OH Jr, Shaker L: Racial differences in trust in health care providers. Arch Intern Med 2006; 166: 896-901.
77. Corbie-Smith G, Thomas SB, St George DM: Distrust, race, and research. Arch Intern Med 2002; 162: 2458-2463.
78. Shavers VL, Lynch CF, Burmeister LF: Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 2002; 12: 248-256.
79. Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, et al: Recruitment experience in the first phase of the African American hereditary prostate cancer (AAHPC) study. Ann Epidemiol 2000; 10(8 suppl):S68-S77.
80. Powell IJ: Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007; 177: 444-449.
81. Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, et al: Putting pharmacogenetics into practice. Nat Biotechnol 2006; 24: 403-410.
82. Zerhouni EA: Research funding. NIH in the post-doubling era: realities and strategies. Science 2006; 314:1088-1090.
83. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.